300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Music
Wine and Spirits
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Art
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Real Estate
Biotech
Transportation
Enterprise
Community
Sporting Goods
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Gibraltar
Burkina Faso
Africa
Singapore
Brazil
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
W. Lowry Caudill, Angel Investor

W. Lowry Caudill

Angel Investor

Durham, United States

W. Lowry Caudill is a Series A investor in Durham focused on Biopharma and Therapeutics. Lowry Caudill is the retired, worldwide President of Pharmaceutical Development for Cardinal Health. The Pharmaceutical Development business unit provided complete development services for the pharmaceutical industry. Caudill led over 1400 employees in nine sites including RTP, San Diego, Somerset NJ, Philadelphia, Manchester UK and Schorndorf GER.In April 2002, Cardinal Health acquired Magellan Laboratories Incorporated, a pharmaceutical development company that Caudill and Alfred Childers co-founded in 1991. Under their leadership Magellan grew to 600 people with 500 employees in RTP and 100 employees in San Diego. Magellan was recognized as one of the fastest growing, privately held companies in the Research Triangle area and received numerous regional and national awards for growth and entrepreneurial development. Magellan was awarded the Triangle Business Journal’s Fast 50 award for nine years and was in the Top 10 for six of the nine years. In 1998, Drs. Caudill and Childers were named Entrepreneur of the Year for North and South Carolina by Ernst and Young, the Kauffman Foundation, USA TODAY, and NASDAQ and were Finalists for the 1998 National Entrepreneur Of The Year. They received two awards from the North Carolina Council for Entrepreneurial Development (CED), the 2002 Entrepreneurial Excellence Award and the 2002 Deal of the Year Award.Caudill received his B.S. degree in Chemistry at the University of North Carolina at Chapel Hill with undergraduate research under the direction of Professor Royce Murray. In 1983, Caudill received his doctorate in Analytical Chemistry from Indiana University under the direction of Professor R. Mark Wightman. His dissertation was titled Development and Application of High Performance Liquid Chromatography with Electrochemical Detection. Upon graduation, he became a research scientist at Baxter-Travenol. In addition to general fanatical activities, he managed a formulation development laboratory, which was responsible for the formulation, development and stability evaluation of frozen premixed parenteral products. In 1987, he joined the Glaxo Research Institute where he played a major role in the establishment of the Analytical Chemistry Department in RTP. Currently marketed product lines which his groups helped develop include Zantac, Imitrex, Zofran, Zinacef, and Ventolin.Caudill is an active entrepreneur and supporter of entrepreneurial endeavors. He serves on the Advisory Board of Southern Capitol Ventures, serves on the Life Sciences Advisory Board of the Aurora Funds and is a member of the Tri-State Investment Group. He is an investor in and member of the Board of Directors of Liquidia Technologies Incorporated. He is a former board member of and investor in Knowledge Vector, Piedmont Pharmaceuticals and Aldagen Inc.Caudill is Chair of the Board of Trustees at the University of North Carolina at Chapel Hill and of the University’s Innovation Circle. He was a Steering Committee member of the $2.4 billion Carolina First Campaign and is chair of the Private Fundraising Steering Committee for the UNC-CH Physical Science Complex. He is an Adjunct Professor of Chemistry at the UNC-CH and a member of the UNC-CH Chemistry Department External Advisory Board. He is a member of the Advisory Working Group for the UNC-CH Entrepreneurship Minor and is chair of the Private Fundraising Campaign for the Entrepreneurship Minor. He and Professor Holden Thorp created and taught the first Scientific Ventures course for the UNC-CH Entrepreneurship Minor. In the spring semesters of 2008 and 2009, he co-taught the Scientific Ventures course with Professor Joe DeSimone. He co-taught the Introduction to Entrepreneurship course in 2007 and 2008 for the Entrepreneurship Minor. He is a member of the Executive Board of The Educational Foundation at UNC-CH. In 2008, he received the Distinguished Alumnus Award from UNC-CH.He is an active member of the American Chemical Society (ACS) and the American Association of Pharmaceutical Scientists (AAPS).Dr. Caudill has chaired numerous boards at Aldersgate United Methodist Church in Durham, NC and presently serves as chair of the Administrative Board and the Building Committee. He was a Team Leader for the Aldersgate 2008 Jamaica Mission Team. Dr. Caudill, and his wife, Suzi, and children reside in Durham. His oldest daughter is a senior at UNC-CH and his son is a sophomore at UNC-CH.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries W. Lowry Caudill invests in

BiopharmaTherapeuticsBiotechnologyNanotechnology

Stages W. Lowry Caudill invests in

Series A

Countries W. Lowry Caudill invests in

United States

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biopharma 1 (100%)
  • Therapeutics 1 (100%)
  • Biotechnology 1 (100%)
  • Nanotechnology 1 (100%)

Investments

CompanyDescriptionRoundLinks
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. $6M / Series A / Jun 14, 2006

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Music
Wine and Spirits
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Art
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Real Estate
Biotech
Transportation
Enterprise
Community
Sporting Goods
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Gibraltar
Burkina Faso
Africa
Singapore
Brazil
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Puerto Rico
Oman
Poland
Cameroon
Guernsey
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does W. Lowry Caudill invest in?

W. Lowry Caudill invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact W. Lowry Caudill?

Public channels for W. Lowry Caudill include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did W. Lowry Caudill last invest?

The most recent investment recorded for W. Lowry Caudill closed in Jun 2006. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
W. Lowry Caudill W. Lowry Caudill Find email